Journal articleMol Cancer Ther2023
Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody-Drug Conjugate.
- Journal
- Mol Cancer Ther
- Published
- 1 June 2023
- Citations
- 9
- License
- cc by-nc-nd
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract cc by-nc-nd
MET, the cell-surface receptor for the hepatocyte growth factor/scatter factor, which is widely overexpressed in various solid cancer types, is an attractive target for the development of antibody-based therapeutics. BYON3521 is a novel site-specifically conjugated duocarmycin-based antibody-drug conjugate (ADC), comprising a humanized cysteine-engineered IgG1 monoclonal antibody with low pmol/L binding affinity towards both human and cynomolgus MET. … Excerpt only: this text is the publisher’s. Read it in full at the source.